Literature DB >> 3885983

Indoramin-prolongation of repolarization time, a mechanism of bradycardia in man?

D W Harron, D P Nicholls, R G Shanks.   

Abstract

The effect of indoramin, a selective alpha 1-adrenoceptor antagonist, on ECG time intervals in normal man was studied. Significant prolongation of QTc was observed after indoramin 100 mg, with no change in QRS duration. In addition, the slope of the RR/QT relationship was changed by indoramin 100 mg. These results suggest that indoramin may have Class III antiarrhythmic activity. If such activity were to affect the SA node, it may explain at least in part the observed lack of reflex tachycardia after indoramin administration.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3885983      PMCID： PMC1463722          DOI： 10.1111/j.1365-2125.1985.tb02642.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  14 in total

1.  Pre- and postsynaptic alpha-adrenoceptor antagonism by indoramin in isolated tissues of the rat.

Authors:  K F Rhodes; J F Waterfall
Journal:  J Pharm Pharmacol       Date:  1978-08       Impact factor: 3.765

2.  Action of indoramin on pre- and postsynaptic alpha-adrenoceptors in pithed rats.

Authors:  D R Algate; J F Waterfall
Journal:  J Pharm Pharmacol       Date:  1978-10       Impact factor: 3.765

Review 3.  Electrophysiological basis for a rational approach to antidysrhythmic drug therapy.

Authors:  E M Williams
Journal:  Adv Drug Res       Date:  1974

4.  Studies relating to the antihypertensive and antidysrhythmic action of indoramin.

Authors:  T Baum; A T Shropshire; D K Eckfeld; N Metz; J L Dinish; J R Peters; F Butz; M I Gluckman
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-08

5.  A comparison of the cardiovascular actions of indoramin, propranolol, lignocaine, and quinidine.

Authors:  B J Alps; E T Borrows; E S Johnson; M W Staniforth; A B Wilson
Journal:  Cardiovasc Res       Date:  1972-05       Impact factor: 10.787

6.  The effect of oral quinidine on intraventricular conduction in man: correlation of plasma quinidine with changes in QRS duration.

Authors:  R H Heissenbuttel; J T Bigger
Journal:  Am Heart J       Date:  1970-10       Impact factor: 4.749

Review 7.  Drugs with a class III antiarrhythmic action.

Authors:  R S Bexton; A J Camm
Journal:  Pharmacol Ther       Date:  1982       Impact factor: 12.310

8.  Cardiovascular effects of indoramin in man--a dose ranging study.

Authors:  D P Nicholls; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

9.  The reversal of experimental cardiac arrhythmias by indoramin (Wy 21901).

Authors:  B J Alps; M Hill; K Fidler; E S Johnson; A B Wilson
Journal:  J Pharm Pharmacol       Date:  1971-09       Impact factor: 3.765

10.  Pharmacological mapping of regional effects in the rabbit heart of some new antiarrhythmic drugs.

Authors:  J S Millar; E M Vaughan Williams
Journal:  Br J Pharmacol       Date:  1983-07       Impact factor: 8.739
View more
  2 in total

Review 1.  Indoramin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and related vascular, cardiovascular and airway diseases.

Authors:  B Holmes; E M Sorkin
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

2.  Effect of acute and chronic oral administration of alfuzosin on baroreflex function and tremor in man.

Authors:  A H Deering; J G Riddell; D W Harron; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.